angiogenesis inhibitor

(redirected from Angiogenesis inhibitors)
Also found in: Dictionary, Thesaurus, Wikipedia.

inhibitor

 [in-hib´ĭ-tor]
1. any substance that interferes with a chemical reaction, growth, or other biologic activity.
2. a chemical substance that inhibits or checks the action of a tissue organizer or the growth of microorganisms.
3. an effector that reduces the catalytic activity of an enzyme.
ACE i's (angiotensin-converting enzyme i's) see angiotensin-converting enzyme inhibitors.
angiogenesis inhibitor a group of drugs that prevent growth of new blood vessels into a solid tumor.
aromatase i's a class of drugs that inhibit aromatase activity and thus block production of estrogens; used to treat breast cancer and endometriosis.
C1 inhibitor (C1 INH) a member of the serpin group, an inhibitor of C1, the initial component activated in the classical complement pathway. Deficiency of or defect in the protein causes hereditary angioedema.
carbonic anhydrase inhibitor an agent that inhibits the enzyme carbonic anhydrase; used in treatment of glaucoma and sometimes for epilepsy, familial periodic paralysis, acute mountain sickness, and kidney stones of uric acid.
cholinesterase inhibitor anticholinesterase.
COX-2 i's (cyclooxygenase-2 i's) a group of nonsteroidal antiinflammatory drugs that act by inhibiting cyclooxygenase-2 activity; they have fewer gastrointestinal side effects than other NSAIDs. Two members of the group are celecoxib and rofecoxib.
gastric acid pump inhibitor an agent that inhibits gastric acid secretion by blocking the action of H+,K+-ATPase at the secretory surface of gastric parietal cells; called also proton pump i.
HIV protease inhibitor any of a group of antiretroviral drugs active against the human immunodeficiency virus; they prevent protease-mediated cleavage of viral polyproteins, causing production of immature viral particles that are noninfective. Examples include indinavir sulfate, nelfinavir mesylate, ritonavir, and saquinavir.
HMG-CoA reductase i's a group of drugs that competitively inhibit the enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, and are used to lower plasma lipoprotein levels in the treatment of hyperlipoproteinemia. Called also statins.
membrane inhibitor of reactive lysis (MIRL) protectin.
monoamine oxidase inhibitor any of a group of drugs that inhibit the action of monoamine oxidase, the enzyme that breaks down norepinephrine and serotonin, prescribed for their antidepressant action; the most widely used ones are isocarboxazid, phenelzine, and tranylcypromine. They are also used in the prevention of migraine.
α2-plasmin inhibitor α2-antiplasmin.
plasminogen activator inhibitor (PAI) any of several regulators of the fibrinolytic system that act by binding to and inhibiting free plasminogen activator. Their concentration in plasma is normally low, but is altered in some disturbances of bodily hemostasis. PAI-1 is an important fast-reacting inhibitor of t-plasminogen activator and u-plasminogen activator. Its synthesis, activity, and release are highly regulated; elevated levels of it have been described in a number of disease states. PAI-2 is a normally minor inhibitor that greatly increases in concentration during pregnancy and in certain disorders. PAI-3 is protein C inhibitor.
platelet inhibitor any of a group of agents that inhibit the clotting activity of platelets; the most common ones are aspirin and dipyridamole. See also antiplatelet therapy.
protease inhibitor
1. a substance that blocks activity of endopeptidase (protease), such as in a virus.
protein C inhibitor the primary inhibitor of activated anticoagulant protein C; it is a glycoprotein of the serpin family of proteinase inhibitors and also inhibits several other proteins involved in coagulation (thrombin, kallikrein, and coagulation factors X and XI) and urokinase. Called also plasminogen activator inhibitor 3.
proton pump inhibitor gastric acid pump i.
reverse transcriptase inhibitor a substance that blocks activity of the reverse transcriptase of a retrovirus and is used as an antiretroviral agent. Some are nucleosides or nucleoside analogues, and those that are not are therefore often called non-nucleoside reverse transcriptase inhibitors.
selective serotonin reuptake inhibitor (SSRI) any of a group of drugs that inhibit the inactivation of serotonin by blocking its absorption in the central nervous system; used as antidepressants and in the treatment of obsessive-compulsive disorder and panic disorder.
serine protease inhibitor (serine proteinase inhibitor) serpin.
topoisomerase i's a class of antineoplastic agents that interfere with the arrangement of DNA in cells.

angiogenesis inhibitor

n.
A drug that blocks angiogenesis in cancerous tissue, thus interfering with tumor growth or metastasis.

angiogenesis inhibitor

one of a group of drugs that prevent the growth of new blood vessels into a solid tumor.

angiogenesis inhibitor

A chemotherapy adjuvant (e.g., TNP-470, Avastin) that inhibits the angiogenesis required for tumour growth and survival, especially for metastastatic tumours.

angiogenesis inhibitor

Oncology A chemotherapy adjuvant which inhibits the angiogenesis required for tumor growth and survive, especially for metastastatic tumors See CAI, CM101, IFN-alpha, IL-12, Marimastat, Pentosan polysulfate, Platelet factor 4, Thalidomide, TNP-470.

angiogenesis inhibitor

One of a range of substances that block the development of new blood vessels (angiogenesis) and show promise as anticancer drugs. Cancers cannot grow beyond microscopic size unless they develop new blood vessels. If this is prevented they will regress or remain dormant and harmless. Research has shown that the angiogenesis inhibitors endostatin and angiostatin are capable of eliminating cancers of the breast, colon, prostate and brain in mice and can do so without undesirable side effects in the short term. These two drugs act in different ways and research on humans with cancer was started in mid-1998. The drugs are believed not to induce drug resistance in mice.
References in periodicals archive ?
Table 6: World Historic Review for Angiogenesis Inhibitors &
Scientists made the discovery after studying cilengitide, an experimental angiogenesis inhibitor which has not yet been licensed for patients.
Moulton stated that she will explore several key areas in her EntreMed-sponsored research efforts over the next two years: "With regard to plaque neovascularization, or new blood vessel growth, research efforts will focus on gaining an understanding of the role angiogenesis inhibitors play in the delay of plaque progression.
Decision Resources' new Emerging Markets Physician & Payer Forum report entitled Emerging Markets Physician & Payer Forum: Payer and Clinician Perspectives on the Role of Premium-Priced Angiogenesis Inhibitors in Brazil and Mexico also finds that--in line with interviewed payer insights--surveyed prescribers of Roche/Genentech/Chugai's Avastin in Brazil and Mexico identify patients with good performance status as prime candidates for Avastin treatment, along with younger patients and those without comorbidities.
As expected, such mice gained little weight when treated with angiogenesis inhibitors.
The Pharmacor 2010 findings from the topic entitled Renal Cell Carcinoma reveal that significant uptake of the angiogenesis inhibitor Votrient/Patorma will be driven by its use in treating advanced renal cell carcinoma, particularly in the first-line setting.
The ability of HDAC inhibitors to synergize with classic chemotherapeutic agents as well as newer signal transduction pathway modulators and angiogenesis inhibitors represents an increasingly appreciated concept meaning that in contrast to the current wave of targeted therapies, the utility of HDAC inhibitors could span multiple cancers and be used alongside a broad range of therapeutics.
Approval of these drugs essentially validated the concept of angiogenesis, and interest in developing angiogenesis inhibitors has increased.
However, opinion leaders have identified angiogenesis inhibitors to be the most promising for prostate cancer.
The report highlights commercial opportunities for angiogenesis inhibitors such as new therapeutic modalities in cancer, ophthalmic diseases, vascular skin diseases, and chronic inflammatory diseases.